JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

JNJ

224.16

-1.45%↓

UNH

370.76

+0.47%↑

TMO

462.35

-1.48%↓

ISRG

452.39

-1.14%↓

ABT

87.56

-2.18%↓

Search

Twist Bioscience Corp

Closed

SectorHealthcare

60.47 3.17

Overview

Share price change

24h

Current

Min

59.89

Max

60.75

Key metrics

By Trading Economics

Income

-3.4M

-31M

Sales

4.7M

104M

Profit margin

-29.419

Employees

979

EBITDA

-3.2M

-24M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

-8.39% downside

Dividends

By Dow Jones

Next Earnings

4 May 2026

Market Stats

By TradingEconomics

Market Cap

1.1B

3.7B

Previous open

57.3

Previous close

60.47

News Sentiment

By Acuity

50%

50%

155 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

3 May 2026, 23:47 UTC

Earnings

National Australia Bank Warns of Economic Shock as 1st Half Profit Falls -- Update

3 May 2026, 22:35 UTC

Earnings

National Australia Bank Holds Dividend Despite 19% 1st Half Profit Drop

3 May 2026, 23:39 UTC

Market Talk

Gold Edge Higher Amid Signs of Resilience -- Market Talk

3 May 2026, 23:34 UTC

Market Talk

Oil Declines Amid Mild Risk-on Sentiment -- Market Talk

3 May 2026, 23:32 UTC

Earnings

National Australia Bank Warns of Economic Shock as 1H Profit Falls -- Update

3 May 2026, 23:30 UTC

Market Talk

Nickel Industries Result Shows Power of Higher Prices -- Market Talk

3 May 2026, 23:20 UTC

Market Talk

RBA Likely to Hike Rates; Guidance and Board Split Key -- Market Talk

3 May 2026, 23:16 UTC

Acquisitions, Mergers, Takeovers

GameStop Is Offering to Buy eBay for $56 Billion, CEO Ryan Cohen Says -- WSJ

3 May 2026, 22:57 UTC

Acquisitions, Mergers, Takeovers

GameStop Is Offering to Buy eBay For $56 Billion, CEO Ryan Cohen Says -- WSJ

3 May 2026, 22:57 UTC

Acquisitions, Mergers, Takeovers

GameStop Has Roughly 5% Stake in eBay, Cohen Says -- WSJ

3 May 2026, 22:57 UTC

Acquisitions, Mergers, Takeovers

GameStop Offering to Buy eBay for $125 a Share, or About $56 Billion, CEO Ryan Cohen Says -- WSJ

3 May 2026, 22:57 UTC

Acquisitions, Mergers, Takeovers

GameStop Is Prepared to Run Proxy Fight If eBay Isn't Receptive to a Deal, Cohen Says -- WSJ

3 May 2026, 22:57 UTC

Acquisitions, Mergers, Takeovers

GameStop Has Around $20 Billion in Debt Financing Committed From TD Bank, Cohen Says -- WSJ

3 May 2026, 22:45 UTC

Market Talk

Global Equities Roundup: Market Talk

3 May 2026, 22:45 UTC

Market Talk

Low-Cost Miners in Spotlight Amid High Energy Prices -- Market Talk

3 May 2026, 22:20 UTC

Earnings

National Australia Bank Holds Dividend Despite 19% 1H Profit Drop

3 May 2026, 22:08 UTC

Earnings

NAB's 1H Included Previously Announced A$1.35B Software Amortization Charge>NAB.AU

3 May 2026, 22:05 UTC

Earnings

NAB 1H Net Interest Income A$9.16B Vs. A$8.445B>NAB.AU

3 May 2026, 22:05 UTC

Earnings

NAB 1H Credit Impairment Charge A$706M Vs. A$348M>NAB.AU

3 May 2026, 22:05 UTC

Earnings

NAB 1H Operating Expenses A$5.02B Vs. A$4.81B>NAB.AU

3 May 2026, 22:04 UTC

Earnings

NAB 1H Net Interest Margin 1.81%>NAB.AU>NAB.AU

3 May 2026, 22:03 UTC

Earnings

NAB 1H Cash Return on Equity Ex-Large Notable Items 11.6%>NAB.AU

3 May 2026, 22:03 UTC

Earnings

NAB 1H Cash Return on Equity 8.5%>NAB.AU

3 May 2026, 22:02 UTC

Earnings

NAB 1H CET1 Capital Ratio 11.65% Vs. 12.01%>NAB.AU

3 May 2026, 22:02 UTC

Earnings

NAB 1H Cash Earnings A$2.64B>NAB.AU

3 May 2026, 22:02 UTC

Earnings

NAB 1H Cash Earnings Ex-Notable Items A$3.59B Vs. A$3.58B>NAB.AU

3 May 2026, 22:01 UTC

Earnings

National Australia Bank Keeps Dividend at A$0.85 >NAB.AU

3 May 2026, 22:01 UTC

Earnings

National Australia Bank 1H Rev A$11.16B Vs. A$10.28B >NAB.AU

3 May 2026, 22:01 UTC

Earnings

National Australia Bank 1H Net A$2.75B Vs. Net A$3.41B >NAB.AU

3 May 2026, 15:06 UTC

Earnings

Berkshire's Greg Abel Marks His First Annual Meeting as CEO. We'd Give Him a B-Plus. -- Barrons.com

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

-8.39% downside

12 Months Forecast

Average 55.33 USD  -8.39%

High 56 USD

Low 55 USD

Based on 4 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

155 / 347 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat